{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:34:32Z","timestamp":1793604872437,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations and slows decline in quality of life compared with placebo. In May 2019, tafamidis received expedited approval from the US Food and Drug Administration as a breakthrough drug for a rare disease. However, at $225 000 per year, it is the most expensive cardiovascular drug ever launched in the United States, and its long-term cost-effectiveness and budget impact are uncertain. We therefore aimed to estimate the cost-effectiveness of tafamidis and its potential effect on US health care spending.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We developed a Markov model of patients with wild-type or variant transthyretin amyloid cardiomyopathy and heart failure (mean age, 74.5 years) using inputs from the ATTR-ACT trial (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial), published literature, US Food and Drug Administration review documents, healthcare claims, and national survey data. We compared no disease\u2013specific treatment (\u201cusual care\u201d) with tafamidis therapy. The model reproduced 30-month survival, quality of life, and cardiovascular hospitalization rates observed in ATTR-ACT; future projections used a parametric survival model in the control arm, with constant hazards reduction in the tafamidis arm. We discounted future costs and quality-adjusted life-years by 3% annually and examined key parameter uncertainty using deterministic and probabilistic sensitivity analyses. The main outcomes were lifetime incremental cost-effectiveness ratio and annual budget impact, assessed from the US healthcare sector perspective. This study was independent of the ATTR-ACT trial sponsor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Compared with usual care, tafamidis was projected to add 1.29 (95% uncertainty interval, 0.47\u20131.75) quality-adjusted life-years at an incremental cost of $1 135 000 (872 000\u20131 377 000), resulting in an incremental cost-effectiveness ratio of $880 000 (697 000\u20131 564 000) per quality-adjusted life-year gained. Assuming a threshold of $100 000 per quality-adjusted life-year gained and current drug price, tafamidis was cost-effective in 0% of 10 000 probabilistic simulations. A 92.6% price reduction from $225 000 to $16 563 would be necessary to make tafamidis cost-effective at $100 000\/quality-adjusted life-year. Results were sensitive to assumptions related to long-term effectiveness of tafamidis. Treating all eligible patients with transthyretin amyloid cardiomyopathy in the United States with tafamidis (n=120 000) was estimated to increase annual healthcare spending by $32.3 billion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Treatment with tafamidis is projected to produce substantial clinical benefit but would greatly exceed conventional cost-effectiveness thresholds at the current US list price. On the basis of recent US experience with high-cost cardiovascular medications, access to and uptake of this effective therapy may be limited unless there is a large reduction in drug costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circulationaha.119.045093","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T05:00:20Z","timestamp":1581483620000},"page":"1214-1224","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":256,"title":["Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1161","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-2979","authenticated-orcid":false,"given":"Dhruv S.","family":"Kazi","sequence":"first","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Boston, MA (D.S.K., S.J.B., C.S., R.W.Y.)."},{"name":"Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (D.S.K., R.W.Y.)."},{"name":"Harvard Medical School, Boston, MA (D.S.K., C.S., R.W.Y.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Bellows","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York (B.K.B., M.S.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J.","family":"Baron","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Boston, MA (D.S.K., S.J.B., C.S., R.W.Y.)."},{"name":"Lahey Hospital and Medical Center, Burlington, MA (S.J.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Shen","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Boston, MA (D.S.K., S.J.B., C.S., R.W.Y.)."},{"name":"Harvard Medical School, Boston, MA (D.S.K., C.S., R.W.Y.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of Missouri\u2013Kansas City (D.J.C., J.A.S., S.V.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[{"name":"University of Missouri\u2013Kansas City (D.J.C., J.A.S., S.V.A.)."},{"name":"Saint Luke\u2019s Mid America Heart Institute, Kansas City, MO (J.A.S., S.V.A., B.W.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Yeh","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Boston, MA (D.S.K., S.J.B., C.S., R.W.Y.)."},{"name":"Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (D.S.K., R.W.Y.)."},{"name":"Harvard Medical School, Boston, MA (D.S.K., C.S., R.W.Y.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne V.","family":"Arnold","sequence":"additional","affiliation":[{"name":"University of Missouri\u2013Kansas City (D.J.C., J.A.S., S.V.A.)."},{"name":"Saint Luke\u2019s Mid America Heart Institute, Kansas City, MO (J.A.S., S.V.A., B.W.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, Kansas City, MO (J.A.S., S.V.A., B.W.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York (B.K.B., M.S.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_4_4_2","unstructured":"Frequently Asked Questions: Breakthrough Therapies. US Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/food-and-drug-administration-safety-and-innovation-act-fdasia\/frequently-asked-questions-breakthrough-therapies. 2019. Accessed October 14 2019."},{"key":"e_1_3_4_5_2","unstructured":"Application Number 211996Orig1s000 212161Orig1s000: Summary Review. Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211996Orig1s000 %20212161Orig1s000SumR.pdf. Accessed August 1 2019."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19232"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_4_8_2","volume-title":"Accessed through Micromedex 2.0","author":"Micromedex Red Book Online","unstructured":"Micromedex Red Book Online. Accessed through Micromedex 2.0. Truven Health Analytics Inc. Accessed October 14, 2019."},{"key":"e_1_3_4_9_2","unstructured":"Medical Expenditure Panel Survey. Agency for Healthcare Research and Quality. https:\/\/meps.ahrq.gov\/mepsweb\/. Accessed August 12 2019."},{"key":"e_1_3_4_10_2","unstructured":"Statistics on Hospital Stays. Healthcare Cost and Utilization Project. https:\/\/hcupnet.ahrq.gov\/#setup. Accessed October 14 2019."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000410"},{"key":"e_1_3_4_12_2","unstructured":"Physician Fee Schedule. Centers for Medicare and Medicaid Services. https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/overview.aspx. Accessed July 19 2019."},{"key":"e_1_3_4_13_2","unstructured":"Howden LM Meyer JA. Age and sex composition: 2010 US Census Brief. https:\/\/www.census.gov\/prod\/cen2010\/briefs\/c2010br-03.pdf. Accessed October 14 2019."},{"key":"e_1_3_4_14_2","first-page":"1","article-title":"Long-term care providers and services users in the United States: data from the National Study of Long-Term Care Providers, 2013\u20132014.","author":"Harris-Kojetin L","year":"2016","unstructured":"Harris-Kojetin, L, Sengupta, M, Park-Lee, E, Valverde, R, Caffrey, C, Rome, V, Lendon, J. Long-term care providers and services users in the United States: data from the National Study of Long-Term Care Providers, 2013\u20132014. Vital Health Stat 3. 2016:x\u2013xii; 1\u2013105.","journal-title":"Vital Health Stat 3"},{"key":"e_1_3_4_15_2","unstructured":"Costs of Care. US Department of Health and Human Services. https:\/\/longtermcare.acl.gov\/costs-how-to-pay\/costs-of-care.html. Accessed May 7 2019."},{"key":"e_1_3_4_16_2","unstructured":"Cost of Care Survey 2018. Genworth Financial Inc. https:\/\/www.genworth.com\/aging-and-you\/finances\/cost-of-care.html. Accessed May 7 2019."},{"key":"e_1_3_4_17_2","unstructured":"Table 2.4.4.U Price Indexes for Personal Consumption Expenditures by Type of Product. US Bureau of Economic Analysis. https:\/\/apps.bea.gov\/iTable\/iTable.cfm?reqid=19&step=2#reqid=19&step=2&isuri=1&1921=underlying. Accessed May 1 2019."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(00)00531-3"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470258019"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.12.010"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1201\/9780429246593"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000042"},{"key":"e_1_3_4_23_2","unstructured":"Medicine Use and Spending in the U.S.: A Review of 2018 and Outlook to 2023. IQVIA Institute. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023. Accessed November 26 2019."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407"},{"key":"e_1_3_4_25_2","unstructured":"Faria R Walker S Palmer S Corbett M Stirk L McDaid C. Tafamidis for Transthyretin Familial Polyneuropathy (TTR-FAP) evidence review group assessment of manufacturer submission. https:\/\/www.york.ac.uk\/media\/crd\/Tafamidis%20ERG%20Report_CRDCHE%20September%204%202013.pdf. Accessed November 26 2019."},{"key":"e_1_3_4_26_2","article-title":"Cost-utility analysis of tafamidis for the treatment of adult patients with transthyretin familial amyloid polyneuropathy in Poland.","volume":"1","author":"Borowiack E","year":"2019","unstructured":"Borowiack, E, Marzec, M, Jarosz, J, Snarska, K, Konopka-Pliszka, M. Cost-utility analysis of tafamidis for the treatment of adult patients with transthyretin familial amyloid polyneuropathy in Poland. Journal of Health Policy and Outcomes Research. 2019;1. https:\/\/www.jhpor.com\/article\/2212-cost-utility-analysis-of-tafamidis-for-the-treatment-of-adult-patients-with-transthyretin-familial-amyloid-polyneuropathy-in-poland. Accessed January 28, 2020.","journal-title":"Journal of Health Policy and Outcomes Research"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0057"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1999"},{"key":"e_1_3_4_29_2","unstructured":"Fast Track. US Food and Drug Administration. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/fast-track. Accessed October 14 2019."},{"key":"e_1_3_4_30_2","unstructured":"Kempf L. CDER\u2019s Office of New Drugs Rare Diseases Program. US Food and Drug Administration. https:\/\/www.fda.gov\/media\/112176\/download. Accessed October 14 2019."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1902943"},{"key":"e_1_3_4_32_2","unstructured":"Orphan Drug Report 2018. EvaluatePharma. https:\/\/info.evaluategroup.com\/OD2018-SOC.html. Accessed October 14 2019."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3451"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3051"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11004"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.119.045093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:51:11Z","timestamp":1715572271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.119.045093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":34,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,4,14]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.119.045093"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.119.045093","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]},"assertion":[{"value":"2019-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}